KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Core Insights - Merck announced results from the final analysis of the pivotal Phase 3 KEYNOTE-B96 trial, demonstrating that KEYTRUDA® (pembrolizumab) in combination with chemotherapy significantly improved overall survival for patients with platinum-resistant recurrent ovarian cancer [1] Group 1: Trial Results - The KEYNOTE-B96 trial, also known as ENGOT-ov65, showed significant improvement in overall survival (OS) as a key secondary endpoint [1]